These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

993 related items for PubMed ID: 25070304

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Palivizumab Prophylaxis in Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection.
    Caserta MT, O'Leary ST, Munoz FM, Ralston SL, COMMITTEE ON INFECTIOUS DISEASES .
    Pediatrics; 2023 Jul 01; 152(1):. PubMed ID: 37357729
    [Abstract] [Full Text] [Related]

  • 7. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
    Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J, IRIS Study Group.
    Pediatr Infect Dis J; 2003 Sep 01; 22(9):823-7. PubMed ID: 14506376
    [Abstract] [Full Text] [Related]

  • 8. Guidelines for palivizumab prophylaxis: are they based on infant's risk of hospitalization for respiratory syncytial viral disease?
    Elhassan NO, Stevens TP, Sorbero ME, Dick AW, Guillet R, Hall CB.
    Pediatr Infect Dis J; 2003 Nov 01; 22(11):939-43. PubMed ID: 14614363
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Hospitalization for respiratory syncytial virus illness in Down syndrome following prophylaxis with palivizumab.
    Paes B, Mitchell I, Yi H, Li A, Lanctôt KL, CARESS Investigators.
    Pediatr Infect Dis J; 2014 Feb 01; 33(2):e29-33. PubMed ID: 23989104
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?
    Hashmi NA, Cosgrove JF, MacMahon P.
    Ir Med J; 2000 Dec 01; 93(9):284. PubMed ID: 11209917
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Ethical considerations and rationale of the MAKI trial: a multicenter double-blind randomized placebo-controlled trial into the preventive effect of palivizumab on recurrent wheezing associated with respiratory syncytial virus infection in children with a gestational age of 33-35 weeks.
    Blanken M, Rovers M, Sanders E, Bont L.
    Contemp Clin Trials; 2012 Nov 01; 33(6):1287-92. PubMed ID: 22820319
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.
    Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, Barsic B.
    Cochrane Database Syst Rev; 2013 Apr 30; (4):CD006602. PubMed ID: 23633336
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A population-weighted, condition-adjusted estimate of palivizumab efficacy in preventing RSV-related hospitalizations among US high-risk children.
    Ambrose CS, Chen X, Kumar VR.
    Hum Vaccin Immunother; 2014 Apr 30; 10(10):2785-8. PubMed ID: 25483483
    [Abstract] [Full Text] [Related]

  • 20. Palivizumab Prophylaxis among Infants at Increased Risk of Hospitalization due to Respiratory Syncytial Virus Infection in UAE: A Hospital-Based Study.
    Elhalik M, El-Atawi K, Dash SK, Faquih A, Satyan AD, Gourshettiwar N, Khan A, Varughese S, Ramesh A, Khamis E.
    Can Respir J; 2019 Apr 30; 2019():2986286. PubMed ID: 31871513
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 50.